THERAVECTYS was founded and incubated within the Pasteur Institute in Paris, and the company maintains close ties with this leading research institution for infectious diseases. Research and development activities at THERAVECTYS are based on 15 years of research conducted at the Pasteur Molecular Virology and Vectorology laboratories.

THERAVECTYS is a development-stage biotechnology company with a novel vaccine platform that can be applied to the treatment and prevention of a broad range of infectious diseases, cancers, and other diseases and conditions. Our first clinical studies will be in HIV/AIDS, using our lead product, a therapeutic vaccine, which has shown promising efficacy and safety in non-human primates.


Date Type Amount Investors Valuation
09/01/12 Other 9.4M Guy Paillaud, John Pieters, Philippe Oddo Unknown